AU2014298373B2 - Anti-GARP protein and uses thereof - Google Patents

Anti-GARP protein and uses thereof Download PDF

Info

Publication number
AU2014298373B2
AU2014298373B2 AU2014298373A AU2014298373A AU2014298373B2 AU 2014298373 B2 AU2014298373 B2 AU 2014298373B2 AU 2014298373 A AU2014298373 A AU 2014298373A AU 2014298373 A AU2014298373 A AU 2014298373A AU 2014298373 B2 AU2014298373 B2 AU 2014298373B2
Authority
AU
Australia
Prior art keywords
antibody
seq
hgarp
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014298373A
Other languages
English (en)
Other versions
AU2014298373A1 (en
Inventor
Pierre Coulie
Julia Cuende Villasur
Gitte DE BOECK
Hans De Haard
Laure Dumoutier
Sophie Lucas
Jean-Christophe Renauld
Michael Saunders
Sebastian VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
ArgenX BVBA
Ludwig Institute for Cancer Research Ltd
Original Assignee
Universite Catholique de Louvain UCL
ArgenX BVBA
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13178958.8A external-priority patent/EP2832747A1/en
Application filed by Universite Catholique de Louvain UCL, ArgenX BVBA, Ludwig Institute for Cancer Research Ltd filed Critical Universite Catholique de Louvain UCL
Publication of AU2014298373A1 publication Critical patent/AU2014298373A1/en
Assigned to UNIVERSITE CATHOLIQUE DE LOUVAIN, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, ARGENX SE reassignment UNIVERSITE CATHOLIQUE DE LOUVAIN Amend patent request/document other than specification (104) Assignors: ARGEN-X N.V., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITE CATHOLIQUE DE LOUVAIN
Priority to AU2019268046A priority Critical patent/AU2019268046A1/en
Application granted granted Critical
Publication of AU2014298373B2 publication Critical patent/AU2014298373B2/en
Priority to AU2021277761A priority patent/AU2021277761A1/en
Assigned to UNIVERSITE CATHOLIQUE DE LOUVAIN, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, argenx BV reassignment UNIVERSITE CATHOLIQUE DE LOUVAIN Request for Assignment Assignors: ARGENX SE, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITE CATHOLIQUE DE LOUVAIN
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
AU2014298373A 2013-08-01 2014-08-01 Anti-GARP protein and uses thereof Active AU2014298373B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019268046A AU2019268046A1 (en) 2013-08-01 2019-11-18 Anti-garp protein and uses thereof
AU2021277761A AU2021277761A1 (en) 2013-08-01 2021-12-03 Anti-GARP protein and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361861008P 2013-08-01 2013-08-01
US61/861,008 2013-08-01
EP13178958.8A EP2832747A1 (en) 2013-08-01 2013-08-01 Anti-GARP protein and uses thereof
EP13178958.8 2013-08-01
EP14167425.9 2014-05-07
EP14167425 2014-05-07
PCT/EP2014/066650 WO2015015003A1 (en) 2013-08-01 2014-08-01 Anti-garp protein and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019268046A Division AU2019268046A1 (en) 2013-08-01 2019-11-18 Anti-garp protein and uses thereof

Publications (2)

Publication Number Publication Date
AU2014298373A1 AU2014298373A1 (en) 2016-02-18
AU2014298373B2 true AU2014298373B2 (en) 2019-12-05

Family

ID=52431038

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014298373A Active AU2014298373B2 (en) 2013-08-01 2014-08-01 Anti-GARP protein and uses thereof
AU2019268046A Abandoned AU2019268046A1 (en) 2013-08-01 2019-11-18 Anti-garp protein and uses thereof
AU2021277761A Abandoned AU2021277761A1 (en) 2013-08-01 2021-12-03 Anti-GARP protein and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019268046A Abandoned AU2019268046A1 (en) 2013-08-01 2019-11-18 Anti-garp protein and uses thereof
AU2021277761A Abandoned AU2021277761A1 (en) 2013-08-01 2021-12-03 Anti-GARP protein and uses thereof

Country Status (16)

Country Link
US (5) US10000572B2 (https=)
EP (2) EP3027650B1 (https=)
JP (3) JP2016529892A (https=)
KR (2) KR20220025174A (https=)
CN (2) CN113583128A (https=)
AU (3) AU2014298373B2 (https=)
BR (1) BR112016002199B8 (https=)
CA (1) CA2919765C (https=)
EA (1) EA035550B1 (https=)
ES (1) ES2860952T3 (https=)
IL (2) IL243899B (https=)
MX (2) MX377091B (https=)
NZ (1) NZ717476A (https=)
SG (2) SG11201600741SA (https=)
WO (1) WO2015015003A1 (https=)
ZA (1) ZA201601085B (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
JP2018529642A (ja) * 2015-07-22 2018-10-11 ホスピタル サント ジョアン デ デューＨｏｓｐｉｔａｌ Ｓａｎｔ Ｊｏａｎ Ｄｅ Ｄｅｕ Ｃａｓｒを発現する癌（例えば神経芽腫）のための免疫療法
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
CN114470194A (zh) * 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20190292254A1 (en) * 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
CN110520524A (zh) * 2017-04-14 2019-11-29 综合医院公司 靶向肿瘤微环境的嵌合抗原受体t细胞
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
US20210038646A1 (en) * 2018-02-12 2021-02-11 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
WO2020079595A1 (en) * 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
KR20210108421A (ko) 2018-12-24 2021-09-02 사노피 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
EP4049675A4 (en) * 2019-10-25 2023-11-22 Daiichi Sankyo Company, Limited COMBINATION OF ANTI-GARP ANTIBODIES AND IMMUNE REGULATOR
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
JP7511377B2 (ja) * 2020-04-16 2024-07-05 デンカ株式会社 アデノウイルスの免疫測定方法及び免疫測定器具
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CA3208624A1 (en) * 2021-01-18 2022-07-21 Shanghai Jemincare Pharmaceutical Co., Ltd. Garp protein antibody and application thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
AU2022363845A1 (en) * 2021-10-11 2024-05-30 Musc Foundation For Research Development Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
US20240042020A1 (en) 2022-07-29 2024-02-08 Abbvie Biotherapeutics Inc. Anti-garp-tgf-beta1/pd-1 combination therapy
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4720122A1 (en) * 2023-06-05 2026-04-08 Pure Biologics Spólka Akcyjna Anti-garp antibodies and methods of use
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
EP3178496A1 (en) * 2007-08-24 2017-06-14 Keio University Fstl1 suppressor for use in the treatment of tumours
AU2008317331B2 (en) * 2007-10-25 2013-08-29 The Scripps Research Institute Antibody-mediated disruption of quorum sensing in bacteria
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
DK3153526T3 (da) * 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
IN2015DN00140A (https=) 2012-08-31 2015-06-12 Argen X Bv
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. X. ZHOU ET AL, "GARP-TGF- Complexes Negatively Regulate Regulatory T Cell Development and Maintenance of Peripheral CD4+ T Cells In Vivo", THE JOURNAL OF IMMUNOLOGY, (2013-04-10), vol. 190, no. 10, pages 5057 - 5064 *
D. Q. TRAN ET AL, "GARP (LRRC32) is essential for the surface expression of latent TGF- on platelets and activated FOXP3+ regulatory T cells", PNAS, (2009-08-11), vol. 106, no. 32, pages 13445 - 13450 *
J. P. EDWARDS ET AL, "Regulation of the Expression of GARP/Latent TGF- 1 Complexes on Mouse T Cells and Their Role in Regulatory T Cell and Th17 Differentiation", THE JOURNAL OF IMMUNOLOGY, (2013-05-03), vol. 190, no. 11, pages 5506 - 5515 *
JULIE STOCKIS ET AL, "Membrane protein GARP is a receptor for latent TGF-Î2 on the surface of activated human Treg", EUROPEAN JOURNAL OF IMMUNOLOGY, (2009-12-01), vol. 39, no. 12, pages 3315 - 3322 *
WANG RUI ET AL, "GARP regulates the bioavailability and activation of TGF[beta].", MOLECULAR BIOLOGY OF THE CELL MAR 2012, (2012-03-15), vol. 23, no. 6, ISSN 1939-4586, pages 1129 - 1139 *

Also Published As

Publication number Publication date
MX377091B (es) 2025-03-07
EP3027650A1 (en) 2016-06-08
JP2020073504A (ja) 2020-05-14
MX2019011952A (es) 2019-12-05
CN113583128A (zh) 2021-11-02
KR20160056880A (ko) 2016-05-20
JP2016529892A (ja) 2016-09-29
JP2022070946A (ja) 2022-05-13
ES2860952T3 (es) 2021-10-05
IL243899B (en) 2020-07-30
US10822424B2 (en) 2020-11-03
US20160272717A1 (en) 2016-09-22
US20200181276A1 (en) 2020-06-11
SG11201600741SA (en) 2016-02-26
MX2016001356A (es) 2016-10-26
EA201690314A1 (ru) 2016-07-29
EP3027650B1 (en) 2021-01-13
US11230603B2 (en) 2022-01-25
EP3786187A1 (en) 2021-03-03
IL243899A0 (en) 2016-04-21
KR102362609B1 (ko) 2022-02-11
CN105658666B (zh) 2021-07-27
WO2015015003A1 (en) 2015-02-05
NZ717476A (en) 2022-04-29
US10604579B2 (en) 2020-03-31
BR112016002199A2 (pt) 2017-08-29
CA2919765C (en) 2023-03-21
SG10201800889SA (en) 2018-03-28
US20200087404A1 (en) 2020-03-19
EA035550B1 (ru) 2020-07-06
IL276106A (en) 2020-08-31
AU2019268046A1 (en) 2019-12-05
KR20220025174A (ko) 2022-03-03
BR112016002199B1 (pt) 2023-10-17
JP7492981B2 (ja) 2024-05-30
BR112016002199B8 (pt) 2024-03-05
US10000572B2 (en) 2018-06-19
AU2021277761A1 (en) 2021-12-23
CN105658666A (zh) 2016-06-08
US20160251438A1 (en) 2016-09-01
ZA201601085B (en) 2022-09-28
AU2014298373A1 (en) 2016-02-18
US20190016811A1 (en) 2019-01-17
CA2919765A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
US11230603B2 (en) Anti-GARP protein
WO2016125017A1 (en) Anti-garp protein and uses thereof
CN112969719B (zh) 双功能融合蛋白及其医药用途
EP2832747A1 (en) Anti-GARP protein and uses thereof
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
WO2022242703A1 (zh) 抗msln抗体及其应用
TW202241944A (zh) 新穎的抗ｇｒｅｍｌｉｎ１抗體
TW202304997A (zh) 新型抗ｃｄ４抗體
TW202144429A (zh) 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
HK1225391B (en) Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1
HK1225391A1 (en) Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1
TW202436350A (zh) 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
CN120813606A (zh) 抗cldn6抗体和使用方法
CN121057749A (zh) 抗cd3多特异性抗体和使用方法
HK40009608B (zh) 针对信号调控蛋白α的抗体和使用方法

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Free format text: FORMER NAME(S): LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; UNIVERSITE CATHOLIQUE DE LOUVAIN; ARGEN-X N.V.

Owner name: UNIVERSITE CATHOLIQUE DE LOUVAIN

Free format text: FORMER NAME(S): LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; UNIVERSITE CATHOLIQUE DE LOUVAIN; ARGEN-X N.V.

Owner name: ARGENX SE

Free format text: FORMER NAME(S): LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; UNIVERSITE CATHOLIQUE DE LOUVAIN; ARGEN-X N.V.

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LUCAS, SOPHIE; COULIE, PIERRE; CUENDE VILLASUR, JULIA; DUMOUTIER, LAURE; RENAULD, JEAN-CHRISTOPHE; VAN DER WONING, SEBASTIAN; SAUNDERS, MICHAEL; DE HAARD, HANS AND DE BOECK, GITTE

PC Assignment registered

Owner name: ARGENX BV

Free format text: FORMER OWNER(S): LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; ARGENX SE; UNIVERSITE CATHOLIQUE DE LOUVAIN

Owner name: UNIVERSITE CATHOLIQUE DE LOUVAIN

Free format text: FORMER OWNER(S): LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; ARGENX SE; UNIVERSITE CATHOLIQUE DE LOUVAIN

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Free format text: FORMER OWNER(S): LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; ARGENX SE; UNIVERSITE CATHOLIQUE DE LOUVAIN